Incruse Ellipta is an inhalant drug containing umeclidinium bromide. Owned by Glaxo Grp England, this drug was granted market authorization on 30 April, 2014. Currently, there are 10 patents for Incruse Ellipta, none of which have expired.
The generic versions of Incruse Ellipta could potentially become available starting from 11 October, 2030, upon the expiry of its last patent. This date is reflective of the conventional patent laws and could be affected by any extensions, litigations, or Para IV filings.
Incruse Ellipta is employed as a long-term, once-daily maintenance treatment for airflow obstruction in patients suffering from chronic obstructive pulmonary disease (COPD), including conditions such as chronic bronchitis and/or emphysema. The active ingredient of this drug, umeclidinium bromide, contributes significantly to its efficacy.
Incruse Ellipta operates under 10 patents, the most recent of which set to expire on 11 October, 2030. This date earmarks the earliest possible release of Incruse Ellipta generic. Below are the details of the patents: